Monte Rosa Therapeutics, Inc. — Q3 2021 Form 10-Q
Reporting period: Three and nine months ended September 30, 2021; comparative periods ended September 30, 2020. Unaudited results. Monte Rosa is a preclinical biotechnology company developing small-molecule molecular glue degraders using its QuEEN platform. It has generated no revenue from drug sales.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $15.1m | $5.5m | $39.0m | $14.1m |
| General and administrative expense | $4.8m | $0.9m | $10.5m | $1.9m |
| Total operating expenses | $19.9m | $6.4m | $49.5m | $16.1m |
| Net loss | $19.8m | $6.6m | $50.5m | $16.2m |
| Basic and diluted net loss per share | $0.43 | $4.29 | $2.85 | $11.01 |
| Cash used in operating activities | Not separately presented for Q3 | $45.2m | $14.5m |
At September 30, 2021, cash and cash equivalents were $367.0m (versus $41.7m at December 31, 2020); restricted cash was $1.7m. Total assets were $384.0m, total liabilities $14.7m, and stockholders’ equity $369.3m. The filing reports no credit facility or committed capital source and no material off-balance-sheet arrangements. There is no meaningful operating margin to report given the absence of revenue.
Changes versus the prior comparable periods
- Q3 net loss increased $13.3m year over year; nine-month net loss increased $34.3m. The increases chiefly reflect the expansion of research and development activity and higher staffing, laboratory, facility, and public-company costs.
- R&D headcount was 73 at September 30, 2021, versus 18 a year earlier; G&A headcount was 19 versus 4.
- Nine-month operating cash use rose to $45.2m from $14.5m. Investing cash use was $6.6m, primarily property and equipment purchases, versus $2.2m.
- Financing provided $377.7m in the first nine months, including preferred-stock financings and IPO proceeds. The June IPO and July underwriters’ option generated $234.8m net proceeds in total; preferred shares converted into common stock at the IPO.
Outlook, risks and unusual items
- Management expects losses, negative operating cash flows, and research and administrative expenses to continue increasing as programs advance. The filing says cash and cash equivalents should fund the operating plan for at least 12 months from issuance; elsewhere, a risk-factor estimate says IPO proceeds and existing cash are expected to fund operations into Q3 2024. These statements use different formulations and assumptions.
- Management planned to submit an IND for a GSPT1-directed candidate in the first half of 2022. All programs remained preclinical; the filing identifies GSPT1, NEK7, CDK2, VAV1, and BCL11A programs. Clinical success, timing, costs, and eventual commercialization are uncertain.
- COVID-19 had not significantly affected operations to date, and vendors were continuing to provide services and supplies, but future disruption remained uncertain. Foreign-currency exposure, principally Swiss franc and euro, and interest-rate sensitivity were disclosed; management said a 100-basis-point rate move would not materially affect cash equivalents.
- Disclosure controls were concluded ineffective. Material weaknesses in financial reporting controls remained unremediated at quarter-end; remediation steps included finance hires, consultants, a new ERP system, and added oversight, with further work planned.
- The company reported no issued patents; its pending applications were early in prosecution. A preferred-stock tranche obligation was settled in February 2021, with a $0.96m fair-value loss recorded during the nine months. The Ridgeline service agreement with a related party was terminated in August 2021.
- No material legal proceedings or material changes to contractual commitments were reported. No subsequent events requiring adjustment or disclosure were identified through issuance.
Important facts for investors to verify
- Reconcile the disclosed cash runway estimates, including the assumptions behind the “at least 12 months” statement and the estimate extending into Q3 2024.
- Track progress toward the planned GSPT1 IND and verify development milestones, costs, and updates for the other preclinical programs.
- Monitor quarterly cash burn, cash deployment, and potential financing needs; management states additional funding will be needed for future development.
- Assess whether the company remediates its material weaknesses and restores effective disclosure controls.
- Review the progress and scope of pending patent applications, given that no patents had issued as of the filing.
- Consider potential dilution from equity compensation and future financings; the filing reported 46.5m common shares outstanding as of November 9, 2021.